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Abstract 
We discuss calculations of probability distribution functions (PDFs) representing 
uncertainties in projecting fatal cancer risk from galactic cosmic rays (GCR) and solar particle 
events (SPEs). The PDFs are used in significance tests of the effectiveness of potential radiation 
shielding approaches. Using Monte-Carlo techniques, we propagate uncertainties in risk coeffi-
cients determined from epidemiology data, dose and dose-rate reduction factors, quality factors, 
and physics models of radiation environments to formulate cancer risk PDFs. Competing mor-
tality risks and functional correlations in radiation quality factor uncertainties are treated in the 
calculations. We show that the cancer risk uncertainty, which is defined as the ratio of the 95% 
confidence level (CL) to the point estimate, is about four-fold for lunar and Mars mission risk 
projections. For short-stay (<180 d) lunar missions, SPEs present the most significant risk, but 
one that is mitigated effectively by shielding, especially for carbon composites structures with 
high hydrogen content. In contrast, for long-duration (>180 d) lunar or Mars missions, GCR risks 
may exceed radiation risk limits, with 95% CLs exceeding 10% fatal risk for males and females 
on a Mars mission. Shielding materials are marginally effective in reducing GCR cancer risks be-
cause of the penetrating nature of GCR and secondary radiation produced in tissue by relativistic 
particles. Currently, based on a significance test that accounts for radiobiology uncertainties in GCR 
risk projection, polyethylene or carbon composite shielding cannot be shown to significantly re-
duce risk compared to aluminum shielding. We therefore conclude that improving knowledge 
of space radiobiology to narrow uncertainties that lead to wide PDFs is the most effective 
approach to ensure radiation protection goals are met for space exploration. 
 
1.  Introduction 
 
This is the first in a three-part series addressing issues related to managing radiation 
risks for lunar and Mars missions that will focus on preflight safety preparations, including risk 
projections and shielding effectiveness. The first part addresses cancer risks, the second part acute 
radiation risks from solar particle events (SPEs), and the third part non-cancer risks including 
damage to the central nervous system (CNS). Exposures to astronauts from galactic cosmic rays 
(GCR)—which are made up of high-energy protons and high-energy and charge (HZE) nuclei, 
and SPEs, which are comprised largely of low- to medium-energy protons—are important safety 
concerns for space exploration. Radiation risks include carcinogenesis, degenerative tissue effects 
such as cataracts (Cucinotta et al., 2001a) or heart diseases (Preston et al., 2003, Howe et al., 2004, 
Yang and Ainsworth, 1982), and acute radiation syndromes (NCRP, 2000). Other risks, such as 
damage to the CNS, are a concern for HZE nuclei (NAS, 1996). In the past, career radiation lim-
its were based on fatal cancer risks. For low Earth orbit (LEO) programs, an excess fatal risk of 
3% is used as criteria for dose limits, which are applied using age- and gender-specific dose to 
risk conversion factors. Although standards for lunar missions are under review at this time, it 
is expected that cancer risks will be the major component of radiation limits until knowledge 
on chronic non-cancer risks from radiation are more firmly established. 
 
Radiation risk projection models serve several roles; these roles include setting dose-to-
risk conversion factors needed to define dose limits, projecting mission risks, and evaluating the 
effectiveness of shielding or other countermeasures. For mission planning and operations, NASA 
uses the model recommended in the NCRP Report No. 132 for estimating cancer risks from space 
(NCRP, 2000). This model, which is similar to approaches described by other radiation risk assess-
ment committees or in the scientific literature, employs a life-table formalism, epidemiological 
assessments of excess risk in exposed cohorts such as the atomic-bomb survivors, and estimates 
of dose and dose-rate reduction factors (DDREFs) and linear energy transfer (LET)-dependent 
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radiation quality factors. Recently, NASA recognized that projecting uncertainties in cancer risk 
estimates along with point estimates should be a requirement for ensuring mission safety, because 
point estimates alone have limited value when the uncertainties in the factors that enter into risk 
calculations are large. Estimates of 95% confidence intervals (CI) for various radiation protection 
scenarios are meaningful additions to the traditional point estimates, and can be used to explore 
the value of mitigation approaches and of research that could narrow the various factors that enter 
into risk calculations. Designing space missions with acceptable levels of cancer risks can take 
several pathways. Because of the penetrating nature of the GCR and the buildup of secondary 
radiation in tissue behind practical amounts of all materials, we argued previously (Cucinotta et 
al., 2001b, 2002, 2004) that improving knowledge of biological effects to narrow confidence 
intervals is the most effective approach to achieve radiation safety goals. 
 
Uncertainties for low-LET radiation, such as gamma-rays, have been reviewed several 
times in recent years, and indicate that the major uncertainty is the extrapolation of cancer effects 
data from high to low doses and dose-rates (NCRP, 1997; BEIR, 1994). Other uncertainties in-
clude the transfer of risk across populations and sources of error in epidemiology data including 
dosimetry, bias, and statistical limitations. For low-LET radiation, probability distribution func-
tions (PDFs) were described previously (NCRP, 1997). In estimating cancer risks for space 
radiation, additional uncertainties occur related to estimating the biological effectiveness of 
protons and heavy ions, and to predicting LET spectra at tissue sites (Cucinotta et al., 2001b). 
The limited understanding of heavy ion radiobiology has been estimated to be the largest 
contributor to the uncertainty for space radiation effects (NAS, 1996), and radiation quality 
factors were found to contribute the major portion of the uncertainties in a previous study 
(Cucinotta et al., 2001b). 
 
In this report, we discuss modifications to our methodology for projecting cancer risk 
probability distributions for space missions and apply the model to several space exploration 
mission scenarios, including the evaluation of potential shielding approaches: First, in our prev-
ious work, we had assumed the normal approximation for summing the additive contributions 
of many radiation components at tissue sites behind spacecraft shielding. The fluence weighted 
variance for each GCR charge and energy group was summed using the square root of the sum 
of the squares to estimate the standard deviation and confidence intervals. In this work, we have 
used direct sampling over organ-weighted LET distributions for the estimation of the 95% CIs, 
and shown that a log-normal distribution results from the analysis. A second modification is 
related to the uncertainties in the radiation quality factors. Previously, we had considered the 
range of experimental data for appropriate endpoints to develop a subjective PDF for the quality 
factor. In this paper, we treat the quality factor, Q(L), and its uncertainties as a functional rela-
tionship, which recognizes that values of Q(L) at different LETs are in fact correlated by under-
lying biophysical processes. The final improvement made here is to accumulate Monte-Carlo 
trials directly from the double-detriment life-table rather than the cancer mortality rate. The life-
table approach is used because, in our previous estimates of cancer risk for the Mars mission 
(Cucinotta et al., 2001b), the upper level of the 95% CI exceeded 10% mortality risk, and we ex-
pect that competing causes of death may significantly compress the higher values in the distribu-
tion. By sampling directly from a life-table, we are also able to study a probability distribution for 
reduced life-expectancy from space radiation exposure. Our risk estimates are based on the quan-
tity risk of exposure-induced death (REID) rather than excess lifetime risk (ELR) to properly 
account for competing risks (Vaeth and Pierce, 1990) and to enable easier comparisons to 
other space mission risks. 
 
Shielding is one approach that can be considered for mitigating radiation risks. 
Theoretical and computational efforts in the 1980’s and 1990’s provided the basic understanding 
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needed to design effective shielding approaches (Wilson et al., 1991, 1995, Cucinotta et al., 
1998a). Materials of low atomic mass, especially hydrogen, are expected to be optimal as radi-
ation shields because they reduce the occurrence of secondary particles (neutrons, protons, and 
other recoils) and are more effective per unit mass of material in slowing or stopping ions in 
atomic collisions and fragmenting HZE ions. However, because relativistic ions in the GCR are 
not appreciably slowed by appreciable amounts of any material and are the largest inducer of sec-
ondary radiation produced in tissues, the role of shielding material selection for GCR is not clear. 
We demonstrate here that shielding materials cannot be shown to have an important role in re-
ducing GCR risks because of their poor attenuation properties in any material combined with 
large risk model uncertainties. In contrast, exposures to SPEs are effectively mitigated by most 
shielding materials, and there is a substantial reduction in mass that occurs when lower mass 
materials are selected for spacecraft structures. 
 
 
2.  Life-Table Methodology 
 
We use the double detriment life-table to estimate radiation cancer mortality risks. In 
this approach, the age-specific mortality of a population is followed over its entire lifespan with 
competing risks from radiation and all other causes of death described (Bunger et al., 1981). For a 
homogeneous population receiving an effective dose E at age aE, the probability of dying in the 
age interval from a to a+1 is described by the background mortality rate for all causes of death, 
M(a), and the radiation cancer mortality rate, m(E,aE,a), as 
 
 ( ) ( , , )( , , ) 11 [ ( ) ( , , )]
2
E
E
E
M a m E a aq E a a
M a m E a a
+=
+ +
 (1) 
 
The survival probability to live to age a following an exposure E at age aE is  
 
 
1
( , , ) [1 ( , , )]
E
a
E E
u a
S E a a q E a u
−
=
= −∏  (2) 
 
ELR, which is the increased probability that an exposed individual will die from 
cancer, is defined by the difference in the conditional survival probabilities for the exposed and 
unexposed groups as 
 
 [ ( ) ( , , )] ( , , ) ( ) (0, , )
E E
E E E
a a a a
ELR M a m E a a S E a a M a S a a
∞ ∞
= =
= + −∑ ∑  (3) 
 
We use a finite cutoff of 101 years for the upper limit in Eq.(3) and expressions below. Although 
a minimum latency time of 10 years is often used for low-LET radiation (NCRP, 2000), we will 
consider alternative assumptions for high-LET radiation. REID is the lifetime risk that an individ-
ual in the population will die from a cancer caused by his or her radiation exposure; it is defined 
by 
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 ( , , ) ( , , )
E
E E
a a
REID m E a a S E a a
∞
=
= ∑   (4) 
 
In general, the value of REID exceeds that of ELR by about 10–20%. Vaeth and Pierce (1990) 
have discussed special cases where ELR is ill-defined and suggested that REID is the preferred 
quantity for radiation protection. The loss of life-expectancy amongst exposure-induced deaths, 
denoted here as LLER, is defined (Vaeth and Pierce, 1990) as 
 
 LLELLER
REID
= , (5) 
 
where the average loss of life-expectancy, LLE,  in the population is defined by 
 
 (0, , ) ( , , )
E E
E E
a a a a
LLE S a a S E a a
∞ ∞
= =
= −∑ ∑ . (6) 
 
 
2.1  Radiation carcinogenesis mortality rate 
 
For projecting lifetime cancer fatality risks, an age- and gender-dependent mortality 
rate per unit dose, estimated for acute gamma-ray exposures, is multiplied by the radiation quality 
factor and reduced by the DDREF (NCRP, 2000); additivity of effects of each component in a rad-
iation field is assumed. Radiation mortality rates are largely modeled using the Japanese atomic-
bomb survivor data. For transferring risks from the Japanese to the U.S. population, two models 
are often considered. The multiplicative transfer model assumes radiation risks are proportional to 
spontaneous or background cancer risks, and the additive transfer model assumes radiation acts 
independently of other cancer risks. However, the NCRP recommends (NCRP, 2000) a mixture 
model with fractional contributions from the multiplicative risk model or additive risk model. 
The radiation mortality rate is written as 
 
 
( ) ( )
( , , ) [ ( , ) ( ) (1 ) ( , )] LE E c E
Q L F L L
m E a a vERR a a M a v EAR a a
DDREF
= + −
∑
 (7) 
 
where ERR and EAR are the excess relative risk and excess additive risk per Sievert, respectively, 
Mc(a) is the gender- and age-specific cancer mortality rate in the U.S. population, F is the tissue-
weighted fluence, L is the LET, and Q is the quality factor. Also in Eq. (7), ν is the fractional 
division between the assumption of the multiplicative and additive risk transfer models. For 
solid cancer, it is assumed that ν=1/2; and for leukemia, it is assumed that ν=0. 
 
 
3.  Uncertainties in the Projection Model 
 
Equation (7) consists of a product of several factors: the ERR or EAR, the background 
cancer rates, Mc, the effective dose represented by the physical dose, FL, times the radiation 
quality factor, Q(L), and the DDREF. The limiting behavior of the addition of many random 
variables is well known as the normal distribution. In contrast, the limiting behavior of the 
multiplication of many random factors will be a log-normal distribution. Equation (7) assumes 
each multiplicative factor is independent. This assumption may not be strictly valid because of 
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possible correlations between factors or non-additivity of different radiation components, since 
cells will be traversed by multiple particles and delta-rays produced by ions passing through ad-
jacent cell layers (Cucinotta et al., 1998b). We next consider estimates of the range of values and 
associated PDFs for each of these factors. Because the risk for longer duration missions exceeds a 
few percent, the upper 95% CI may exceed 10%. In such cases, the sampling of rates is insufficient, 
and the expression for the REID given by Eq. (4) must be used because of competing risks from 
other causes of death that will reduce the likelihood of very large radiation risks. Therefore, in the 
sampling approaches described below, trials are accumulated for the REID rather than the mortal-
ity rate. A criteria used in our approach for formulating PDFs for various factors is to ensure the 
PDFs are peaked at the values recommended by the NCRP (NCRP, 2000), such as the DDREF 
and Q, or in the current physics models of radiation environments and transport used in mission 
projections or spacecraft designs. We next discuss the uncertainties in the projection model. 
 
 
3.1  Uncertainties in low linear energy transfer epidemiology data 
 
For sampling purposes, the low-LET mortality rate per Sievert, mL, is written 
 
 0 ( , , )( , , ) x D s T Bl x
Dr
m E a a x x x xm E a a
DDREF x
= , (8) 
 
where m0 is the baseline mortality rate per Sievert (see Eq. (7)) and the xα are quantiles (random 
variables) whose values are sampled from an associated PDF, P(xα). Note that the DDREF applies 
only to the solid cancer risk and not to the leukemia risk under the stated assumptions. The NCRP 
Report 126 (NCRP, 1997) defines the following subjective PDFs, P(xα), for each factor that 
contributes to the low LET-risk projection: 
 
1. Pdosimetry represents random and systematic errors in the estimation of the doses received by 
atomic-bomb blast survivors. It is assumed as a normally distributed PDF for bias correction 
of random and systematic errors in the dosimetry (DS86) with mean 0.84 and standard 
deviation 0.11; 
2. Pstatistical represents the distribution in uncertainty in the risk coefficient r0. It is assumed as a 
normally distributed PDF with a mean of 1 and a standard deviation of 0.15; 
3. Pbias represents any bias resulting for over- or under-reporting cancer deaths. Pbias is assumed 
as a normal distribution with a most probable value of 1.1 and a 90% CI from 1.02 to 1.18 
corresponding to a standard deviation of 0.05; 
4. Ptransfer represents the uncertainty in the transfer of cancer risk following radiation exposure 
from the Japanese population to the U.S. population. Both additive and relative risks models 
were considered by the NCRP 126 report (NCRP, 1997) in assessing the uncertainties in such 
transfer. Ptransfer is log-normal with a mean of 1 and a standard deviation of 0.26 (GSD=1.3); 
5. PDr represents the uncertainty in the knowledge of the extrapolation of risks to low dose 
and dose-rates embodied in the DDREF. The NCRP assumed PDr to be a truncated triangle 
distribution starting at 1 and ending at 5 with a peak at 2 and with a relative value of ¼ or ½ 
at 1 or 5, respectively, compared to the peak values for the DDREF at 2. This PDF is used to 
scale the low-LET risk coefficient (mortality rates) in our estimates for space radiation. 
 
The NCRP also considered a PDF for bias correction in projection of cancer risks over a lifetime. 
It is ignored herein, however, because the astronaut population is generally over age 30 y and the 
Japanese data are now complete for these ages. We also ignore the assumed “unknown 
uncertainties” from the NCRP 126 report (NCRP, 1997). 
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3.2  Uncertainties due to dose-rate and protraction effects for ions 
 
For low dose-rate and protracted proton and HZE radiation exposure of more than a few 
months, new biological factors may influence risk assessments including redistribution in the cell 
cycle, repopulation, or promotional effects, especially when particle fluences are large enough to 
lead to multiple hits of target cells or surrounding cells and tissue environments. Also, not only 
are there no human data for protons and HZE ions, there are very little experimental data at low 
dose-rates for these particles. Confidence in using radio-epidemiological data for acute (A-bomb 
survivors) or fractionated (patients) data is decreased when applied to protracted exposure. Burns 
et al. (1994) found split doses of argon ions separated by a few hours up to one day increased the 
risk of skin cancer in rats. Alpen et al. (1994) found using seven 2-week fractions of 0.07 Gy of 
iron increased risk to 50% compared to a single acute dose of 0.4 Gy for Harderian gland tumors 
in mice. A study of chromosomal aberrations in human lymphocytes (George et al., 2002 for 
acute and low dose-rates (0.08 Gy/hr) with 250 MeV protons showed less sparring than found 
for gamma-rays. The Skyhook study of Ainsworth (1986) considered life-shortening in mice 
comparing single acute with weekly fractions of several ions; however, the results were 
unclear with regards to any increase or decrease in risk. 
 
For gamma-rays and neutrons, a number of studies for cancer induction or life-
shortening in mice exist, showing sparring effects for gamma-rays and that neutron effects 
may be increased due to protraction under certain conditions in some tissues (Ullrich, 1984; 
NCRP, 1990). Important questions related to the differences in lifespan, cell turnover rates, or 
mechanisms of initiation or promotion in humans and mice make estimates of the effects of 
protraction on risk difficult. If protraction effects do increase the risk from high-LET radiation, 
such effects would be more important for a Mars mission than for the shorter lunar missions. In 
space, each cell will be traversed about every two to three days by a proton or delta-ray produced 
by ions in adjacent cells, and with a decreasing frequency from weeks to months as the charge of 
the HZE nuclei increases (Cucinotta et al., 1998b). Studies of mixed fields of protons and HZE 
ions are needed to understand uncertainties in dose-rate and protraction effects from space rad-
iation. Uncertainties related to radiation quality, dose-rate, and protraction could lead to correla-
tions that will be difficult to describe when based on limited experimental data. Methods to treat 
correlation effects will be needed when data on protraction effects become available. 
 
 
3.3  Radiation quality and latency or temporal patterns of risk 
 
An additional radiation quality uncertainty is introduced by the scaling assumption used 
in Eq. (7) because the time dependence for low- and high-LET radiation is assumed to be identical. 
Data on tumors or genomic instability in mice with neutrons (Ullrich, 1984; Ullrich and Ponnaiva, 
1998; NCRP, 1990) and the studies of rat or mammary carcinogenesis with HZE nuclei (Burns, et 
al., 1994; Dicello et al., 2004) suggest that the latency time is appreciably reduced for high-LET 
radiation compared to low LET-radiation. Sparse data are available to estimate the impact of 
these differences on uncertainties. A radiation quality-dependent latency is more important in the 
additive transfer model than in the multiplicative transfer model, especially at younger ages of 
exposure. Also, for high-LET radiation, a constant ERR with time after exposure assumption, 
following an early latency period, is difficult to prove based on current animal carcinogenesis 
data. We ignore these uncertainties; however, we replace the 10-year minima latency assumption 
made for low LET by the step-in latency model (Pierce et al., 1996) used for the leukemia risk. 
The effects of these assumptions will need to be addressed when data and knowledge on 
underlying mechanisms become available. 
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3.4  Uncertainties in quality factors 
 
Radiation quality factors represent the largest uncertainty in estimating space radiation 
cancer risks. Past reviews on the relative biological effectiveness of high-LET radiation include 
ICRP Report 40 (1986), NCRP Report 104 (1990), and more recently ICRP Report 92 (2003). 
The practice, followed by committees, of assigning radiation quality factors is to consider an 
average of the relative biological effectiveness (RBE) factors at low doses (RBEmax) for the most 
relevant experimental endpoints. Uncertainties in assignment of RBEs for protons and heavy ions 
arise for several reasons including sparseness of data for tumorigenesis in animal models or sur-
rogate tissue or cellular endpoints, variability in reference radiation and doses and dose-rates 
employed, and lack of data over the LET range of interest. Also, linearity at low dose or dose-
rates for the reference radiation or ions is frequently not sufficiently established in experiments. 
Statistical limitations often hinder studies at the low dose-rates of interest for space radiation 
protection. For high-LET radiation, a turnover or bending found in the dose response for tumor 
induction and neoplastic transformation is observed at moderate doses, presenting further 
uncertainties in estimating the effectiveness of high-LET radiation at low dose-rates. 
 
Figure 1 shows representative examples of the ratio of RBEmax to Q for mouse tumors, 
cell transformation or mutations, or cytogenetic endpoints. The ratio is often two- to three-fold 
higher or lower than unity, indicating the expected deviation from Q in available data. Table 1 
shows LET values at the maximum RBE found in past studies selected from experiments where 
>5 ions were employed. Large deviations from the Q peak at 100 keV/µm are observed in these 
experiments with a range from about 50 to 190 keV/µm for the peak. These data are largely from 
the facilities at Berkeley, Calif., Darmstadt, Germany, Chiba, Japan, and the Alternating Gradient 
Synchrotron (AGS), Brookhaven National Laboratory, Upton, NY. The number of past studies  
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Figure 1. Comparison of ratio of RBEmax to Q for several endpoints found with proton, alpha 
particle, and heavy ion irradiations (reference experiments listed in Table 1). 
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Table 1. Approximate LET where maximum RBE was found in biological experiments 
Biological system Endpoint LET at peak 
RBE, keV/µm 
LET range (no. of 
ions studied) 
Reference 
Human TK6 
lymphoblasts cells 
TK mutants 60 32–190 (6) Kronenberg (1994) 
Human TK6 
lymphoblasts cells 
HPRT mutants 60 32–190 (6) Kronenberg (1994) 
Human lung 
fibroblasts 
HPRT mutants 90 20–470 (9) Cox and Masson 
(1979) 
Human skin 
fibroblasts 
HPRT mutants 150 25–920 (7) Tsuoboi et al. 
(1992) 
V79 Chinese 
hamster cells 
HPRT mutants 90 10–2000 (16) Kiefer et al. (1994); 
Belli et al. (1993) 
Caenorhabditis 
elegans 
Recessive 
lethal 
mutations 
190 0.55–1110 (14) Nelson et al. (1989) 
Human 
lymphocyte cells 
Chromosomal 
exchanges 
147 0.4–1000 (10) George et al. 
(2003) 
Human fibroblast 
cells 
Chromatid 
breaks 
80-185 13–440 (6) Kawata et al. 
(2001) 
C3H10T1/2 mouse 
cells 
Transformation 140 10–2000 (10) Yang et al. (1989) 
C3H10T1/2 mouse 
cells 
Transformation 90 20–200 (10) Miller et al. (1995) 
Syrian hamster 
embryo (SHE) 
cells 
Transformation 90 20–200 (8) Martin et al. (1995) 
Mouse (B6CF1) H. gland 
tumors 
185* 2–650 (6) Fry et al. (1985) 
Mouse (B6CF1) H. gland 
Tumors 
193 0.4–1000 (7) Alpen et al. (1993) 
Mouse (CB6F1)  Days life lost 52* 50–500 (6) Ainsworth (1986) 
*Track-segment or spread out Bragg peak (SOBP) irradiations. 
 
 
and endpoints used are limited if viewed as surrogate endpoints for human carcinogenesis. Addi-
tional data for more appropriate endpoints should become available in the next few years at the 
NASA Space Radiation Laboratory (NSRL). Track structure models suggest that each ion species 
would have distinct RBE curves of similar shape, but with curves for lower charge ions peaking 
at a lower LET than higher charged ions (Katz et al., 1971; Cucinotta et al., 1996; Nikjoo et al., 
1999). Furthermore, above about 1 MeV/u lower charged ions have a higher biological effec-
tiveness than higher charged ions of identical LET. Based on track structure models, we expect 
that data sets that consider only a few ions are insufficient for defining the radiation quality de-
pendence of Q. LET response curves also are predicted to depend on the target size (e.g., for gene 
or chromosome region) and intrinsic radiation sensitivity, which includes the competition with 
cell death. These factors likely vary between tissues. 
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To account for uncertainties in quality factors, we introduce a trial function that has a 
shape guided by both experimental data and biophysical models, and sample from distributions of 
parameters that enter into the functional form. The Q(L) trial function is defined as 
 
 
0
0
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m
L L
Q L AL B L L L
C L L L
<⎧⎪= − ≤ <⎨⎪ ≥⎩
 (9) 
 
We sample values of L0, Lm, p, and the maximum value Qm(Lm) from PDFs described below. 
Using Eq. (9), we can solve for values of the constants A, B, and C. Often-discussed issues on 
the definition of Q(L), as embodied in Eq. (9), are the value of slope p that controls the decrease 
in Q(L) above a maximum, the maximum value of Q(L), the LET where the maximum occurs, Lm, 
and the minimum LET where Q(L) rises above unity, L0 . We note the ICRP-60 Q-function corre-
sponds to L0=10 keV/µm, Lm=100 keV/µm, p = ½, and Qm=30 such that A=0.32, B=2.2, C=300, 
and the ICRP-26 Q-function, L0=3.5 keV/µm, Lm=172.5 keV/µm, p=0, and Qm=20. 
 
The parameter samplings are based on the following assumptions for PDFs: 
 
a. L0: equal probability between 5 and 10 keV/µm, and decreasing to zero at 1 keV/µm or 
above 15 keV/µm. 
b. Lm: equal probability for LET values between 75 and 150 keV/µm, and decreasing to zero 
at 50 keV/µm or above 250 keV/µm. 
c. p: equal probability between p=1/2 and 1, and decreasing to zero at p<0 or p>2. 
d. Qm: log-normal distribution with mean value of 30 and geometric standard deviation 
(GSD) of 1.8. 
 
Figure 2 shows examples of trial Q(L) functions that contribute in the sampling procedures, and 
Figure 3 shows the resulting average Q(L) and 95% CI after 20,000 trials. The resulting range is 
smaller than in our previous report (Cucinotta et al., 2001b); however, it should be a reasonable 
estimate when the effects of dose protraction are not included in the uncertainty analysis. 
 
 
LET, keV/µm
1 10 100 1000
Q
j(L
)
0
20
40
60
80
100
 
Figure 2. Examples of trial quality factor func-
tions used in uncertainty calculations. A distinct 
curve is generated for each trial. 
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Figure 3. Average quality factor (circles) and 
95% CI vs. LET from Monte-Carlo sampling 
over trial function of Eq. (9). 
 
 
3.5  Uncertainties in physics: environments and transport codes 
 
Space dosimetry and radiation transport codes have been studied extensively in the past 
and, although there are no major scientific questions that lead to errors in the assessment of space 
radiation environments, there are uncertainties due to limitations in dosimetry flown on past space 
missions. For application of computational models, the level of detail used in transport code com-
parisons is often limited, with common simplifications including the use of an aluminum equival-
ent shielding approximation, simplified geometries, and no description of orientation effects. Ap-
proaches to assess the errors in space dosimetry include inter-comparison of different dosimetry 
on the same missions as well as inter-comparison of results of space radiation transport models. 
Although statistical errors in the assessment of physical doses are quite small (<5%), inter-
comparisons between laboratories have shown differences on the order of 10% for absorbed dose 
(Badhwar, 1997). Comparisons of transport calculations to measurements of LET spectra or dose 
equivalent should consider response functions of different detector types to charged particles or 
neutrons (Nikjoo et al., 2002). Commonly used detectors are tissue equivalent proportional coun-
ters (TEPCs), silicon detectors, and CR-39 plastic track detectors. However, good agreement has 
been found in the limited number of comparisons that have been made (e.g., Badhwar and 
Cucinotta, 2000; Kim et al., 2003; Shinn et al., 1998), especially when detector response 
functions are represented in the comparisons. 
 
Models of the GCR environment rely on the large number of spaceflight and balloon 
measurements that have been made, and apply the diffusion theory of Parker (1965) to describe 
the modulation of the GCR over the solar cycle. The root mean square error for GCR environ-
mental models is less than 10% for the major GCR elements and less than 15% for most minor 
elements (Badhwar and O’Neill, 1994a; Badhwar et al., 1994b; O’Neill, 2005). The isotopic com-
position of the GCR is also represented in transport codes (Cucinotta et al., 2003) used in risk 
calculations. SPE spectra vary from event to event, and no method is available to predict the 
fluence, energy spectra, or dose-rates of a future event. In this report, we discuss calculations 
for the large SPE of August 1972; risk assessment approaches to SPEs for acute risks will be con-
sidered in a future report. Transport codes rely on databases for nuclear interaction cross sections, 
including inclusive single differential in energy or total fragment production cross sections for 
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projectile fragments and double differential in energy and angle for lighter mass secondaries 
(neutrons, hydrogen and helium ions, and mesons). Cross-section data are sparse for some 
projection-target combinations and in the number of energies, especially above 1,000 MeV/u. 
Three-dimensional aspects of transport from angular scattering, a small correction for high-
energy ions, are expected to be an important correction for neutrons and other light mass ions. 
Computer codes that use multi-group methods or Monte-Carlo simulations to describe angular 
effects on neutron transport have been developed for GCR shielding applications. The Monte-
Carlo codes are limited by the computational times needed to describe spacecraft with thousands 
of parts, and the multi-group methods are limited by the ability to describe complex geometries. 
However, because flight measurements and the results of the HZETRN code (Wilson et al., 1995) 
using the Badhwar-O’Neill GCR input spectra (Badhwar and O’Neill, 1994a) and the quantum 
multiple scattering fragmentation (QMSFRG) nuclear interaction database (Cucinotta et al., 
2003) are in good agreement, it is unclear whether such developments will have an important 
impact on risk assessment. 
 
Differences between transport models and flight dosimetry that account for the de-
tectors’ response to different radiation components are generally small with absolute differences 
within 10% for the GCR dose and 20% for the GCR dose equivalent (Badhwar, 1997; Badhwar 
and Cucinotta, 2000 Cucinotta et al.; 2000; Cucinotta et al., 2003). Measurements of dose or 
dose-equivalent may not provide sufficient information on possible errors in predicting LET 
spectra because compensating errors can occur. Also, neutron spectra are difficult to assess within 
complicated spacecraft and tissue geometries. In particular, measurements or calculations of neu-
tron spectra are expected to lead to uncertainties in LET spectra in the LET range from about 30 
to 300 keV/µm where recoil nuclei deposit the majority of the energy. Neutrons also cause a low-
LET gamma-ray component that is often ignored in calculations. Larger errors are expected at 
higher LET values, where stopping nuclei dominate, and may be difficult to define due to local 
tissue variations. We expect uncertainties to be larger at high-LET values, where the role of 
local target recoils and stopping GCR primaries is difficult to describe. 
 
The PDFs for the uncertainties in LET spectra should ensure that the resulting dose 
equivalent is consistent with transport code comparisons to past spaceflight measurements for 
GCR. A quantile, xL, associated with a normal distribution, PF(xF=F/F0), is used with a standard 
error that increases with LET to represent the higher uncertainties expected for prediction of neu-
tron effects and difficulty in precisely defining stopping ions in complex geometries. The PDF is 
given a median of x0F=0.65 to ensure that the resulting dose equivalent is in agreement with 
values from the prior comparison between transport codes and flight measurements cited 
above. Standard deviations for different LET regions are given in Table 2. 
 
 
Table 2. Standard deviations (S.D.) for uncertain-
ties in model LET spectra for several LET regions 
LET Interval S.D. for dF/dL 
<30 keV/µm  1.0 
30–300 keV/µm  2.0 
>300 keV/µm  2.5 
 
 
Figure 4 and Figure 5 illustrate the errors assigned to environmental and physical factors in 
evaluating LET spectra at tissue sites. 
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Figure 4. Calculation of tissue-weighted integral LET 
spectra and 90% CI for space environmental and trans-
port uncertainties for 20 g/cm2 aluminum shield for one 
year in deep space. 
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Figure 5. PDF for GCR effective dose for 20 g/cm2 aluminum 
shield for 600-d Mars swingby mission. The point estimate is 0.86 
Sv, and the 95% CI for uncertainties in LET distribution at tissue 
sites is [0.78, 1.08] Sv. Only uncertainties in physics are included. 
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3.6  Life-tables and population cancer rates 
 
Although radiation risk calculations are based on population data, they are used to 
estimate risks for individuals. While population data reflect gender differences, these data also 
change with calendar year and are often used for projections far into the future. For the astronaut 
population, the appropriateness of using the U.S. average population can be questioned because 
the so-called “healthy worker” effect is expected for astronauts. In the average U.S. population, 
females have a longer lifespan than males, partially due to the overall lower risk of cancer. The 
formalism of Eq. (1) through Eq. (7) shows that two counteracting effects arise when we attempt 
to determine whether the use of population rates representative of a healthier population as com-
pared to the U.S. population would decrease or increase the risk of radiation carcinogenesis. First, 
the population survival function acts to decrease radiation risks, especially at older ages. Therefore, 
an improved survival function acting alone will increase the risk from radiation. However, an im-
proved survival function also suggests lower background cancer rates, making up some fraction 
of the delay in mortality. In the multiplicative transfer model, radiation risks are reduced by the 
healthy worker effect, in part due to a reduced natural incidence of cancer. Thus, the portions of 
risk transfer assigned to multiplicative and additive transfer act in opposition if a healthy worker 
effect is present. In a model where a geometric average of these two models is used, we expect a 
minor change if an improved life-table and background cancer rates are assumed. The role of the 
survival function is also reduced if, as has been suggested in some studies (Preston et al., 2003), 
solid cancers would display a plateau at long times after exposure (>30 y). This discussion points 
to the need for better understanding of the biological basis for risk transfer models and depend-
ence of risk after long follow-up times. 
 
To estimate the effects of gender- and calendar-year-specific population data on 
radiation risk projections, Table 3 shows results for males and females receiving an exposure of 
1 Sv where radiation rates are fixed but life-tables and/or cancer rates for females and males, re-
spectively, are varied between the genders. It can be seen that these changes lead to variations of 
no more than +20%. The higher cancer risk for females is thus largely due to the additional risks 
for breast and ovarian cancer, with lifespan differences between genders making a minor contri-
bution. The Social Security Administration (SSA, 2004) has looked at life-expectancy projections 
over the next 75 years, a time that spans the period of the Mars exploration program. The SSA results, 
given in Figure 6, show about a six-year increase in life-expectancy for males and females over 
this time period. Since in the year 2000 life-tables females have about a six-year longer life-ex-
pectancy than males, the examples shown in Table 3 for males using the female population rates 
also serve to illustrate the change expected owing to calendar-year evolution of population rates 
over the course of the next 75 years. The differences between males and females also suggest the 
level of change that could occur if healthy worker population rates were modeled. The compari-
son indicates changes on the order of 10% over the next few decades, but larger changes would 
occur using a purely multiplicative transfer model. 
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Figure 6a. Actual or projected male median lifespan at birth vs. calendar year 
(from SSA, 2004). 
 
 
 
Figure 6b. Actual or projected female median lifespan at birth vs. calendar 
year (from SSA, 2004). 
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Table 3a. Sensitivity study of REID(%) for males at 1-Sv effective dose estimated using 
male radiation rates and female life-table and population cancer rates. Percent changes 
from altering these background rates are listed in parenthesis 
Age, yr Males Males with 
female 
M(a), Mc(a) 
Males with 
female  
M(a) 
Males with 
female 
 Mc(a) 
30 4.84 5.20  (+7.4) 5.99 (+23.8) 4.23  (–12.6) 
40 3.76 4.08  (+8.5) 4.63 (+23.1) 3.33  (–11.4) 
50 2.59 2.83  (+9.3) 3.21 (+23.9) 2.29  (–11.6) 
 
Table 3b. Same as Table 3a for females 
Age, yr Females Females with 
male 
M(a), Mc(a) 
Females with 
male 
M(a) 
Females with 
male  
Mc(a) 
30 6.45 6.24  (–3.3) 5.20 (–19.4) 7.79  (+20.8) 
40 4.83 4.63  (–4.1) 3.91 (–19.1) 5.77  (+19.5) 
50 3.27 3.13  (–4.3) 2.62 (–19.9) 3.92  (+19.9) 
 
 
4.  Probability Distribution Functions for Space Exploration Missions 
 
The cancer risk projection for space missions is found by folding predictions of the 
tissue-weighted LET spectra behind spacecraft shielding, dF/dL, with the radiation cancer 
mortality rate to form a rate for a trial J: 
 
 ( , , ) ( , , ) ( )J E lJ E trial J L J
dFm E a a m E a a dL LQ L x
dL − −
= ∫ . (10) 
 
(Not shown are quantiles associated with low-LET mortality rate.) Alternatively, particle-specific 
energy spectra, Fj(E), for each ion, j, can be used: 
 
 ( , , ) ( , , ) ( ) ( ) ( ( ))J E lJ E j trial J L J
j
m E a a m E a a dEF E L E Q L E x− −= ∑∫  (11) 
 
The result of Eq. (10) or (11) is then inserted into the expression for the REID of Eq. (4). In 
implementing a numerical procedure, we group the PDFs related to the risk coefficient of the 
normal form, consisting of the dosimetry, bias, and statistical uncertainties, into a combined PDF, 
Pcmb(x). After accumulating sufficient trials (~105), the results for the REID estimates are binned 
and the median values and confidence intervals are found. 
  
 We use the χ2 test for determining whether PDFs for two distinct shielding configurations 
or materials significantly differ. We denote the calculated PDFs for a REID of Ri for two config-
urations or materials as p1(Ri) and p2(Ri), respectively. Each p(Ri) follows a Poisson distribution 
with variance, ( )ip R . The chi-squared, χ2 test for characterizing the dispersion between the 
two distributions is then 
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Once χ2 is determined, the probability P(n,χ2) that the two distributions are the same is 
calculated. If χ2 is sufficiently large such that P(n,χ2) is less than about 20%, this is an indication 
that we can conclude that the two distributions lead to distinct cancer risks from GCR and/or SPEs 
with the material with the lowest mean and upper 95% CL values preferred for radiation protec-
tion. However, the opposite result indicates that either the materials are approximately the same, 
or that the uncertainties in risk models prevent us from concluding that either configuration or 
material is superior for radiation protection properties. We evaluate χ2 for the LET-dependent 
parts of the uncertainties (quality factors and physics) separately, since only these contributions 
explicitly depend on the modification of radiation fields by shielding. 
 
 
5.  Results 
 
In the results described next, we use values of ERR and EAR for solid cancers from the 
Japanese Longitudinal Lifespan Study Report No. 13 (Preston et al., 2003). Note that these values 
for females were found to about 15% lower than the prior Report No. 12 (Pierce et al., 1996) used 
by NCRP Report No. 132 (NCRP, 2000) and values for males were nearly the same in Reports 12 
and 13. Values for ERR and EAR for leukemia were not updated in the latest report; we use the 
values from Pierce et al. (1996). We also use life-tables (CDC, 2002 and background cancer mor-
tality rates (SEER, 2000) for the average U.S. population for the year 2000. For models, we use 
the GCR free space environment of Badhwar et al. (1994b), the high charge and energy transport 
(HZETRN) code (Wilson et al., 1991, 1995), and the QMSFRG model of nuclear fragmentation 
cross sections (Cucinotta et al., 2003). The CAMERA model (Billings et al., 1973) is used for 
organ shielding with tissue-weighting coefficients (NCRP, 2000). Figure 7 shows calculations 
of the point dose equivalent and the effective dose (tissue averaged organ dose equivalent) for 
various shielding materials calculated by the HZETRN/BRYNTRN codes for the solar minimum 
GCR environment and the August 1972 SPE. Calculations predict that the effects of SPE are 
readily mitigated by shielding (the effects of GCR are not), and that tissue shielding reduces the 
differences expected when comparing materials. For hydrogen shielding, the GCR effective dose 
is larger than the point dose because target fragments in tissue contribute about 50% of the effec-
tive dose, even though very little secondary radiation is produced directly in the hydrogen shield. 
Clearly, calculations or measurements of point dose equivalents misrepresent the effectiveness of 
shielding because of the role of secondary radiation produced in tissue. 
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Figure 7. Point dose equivalent (upper panel) and effective 
dose (bottom panel) behind various shields for solar minimum 
GCR and August 1972 SPE (the units for the SPE doses are 
for total event and not necessarily per year). 
 
Spacecraft typically have aluminum as a major constituent, and transport calculations 
often scale material thicknesses under an aluminum-equivalent areal-density t=ρx, approximation 
where ρ is mass density, x, is physical thickness, and materials are scaled to aluminum by the ratio 
of the range of 60 MeV protons or a similar approximation. Figure 8 shows thickness distribu-
tions in aluminum-equivalent depths for the Apollo Command module and several more recent 
spacecraft used in LEO. Minimal areal-densities of spacecraft such as Skylab, the Space Shuttle, 
or the International Space Station (ISS) are 2 to 5 g/cm2; however, averages are in the range from 
10–25 g/cm2 of aluminum-equivalent material. The launch requirements for deep space may re-
quire reduced shielding mass compare to these vehicles. Many dose calculations in the scientific 
literature underestimate the inherent shielding of spacecraft and tissues. For our calculations, we 
use 5, 10, and 20 g/cm2 as representative of minimal or average shields. Complex shielding con-
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figurations are a superposition of these results (Cucinotta et al., 2000), but transition effects 
between materials should be considered. 
 
Figure 9 shows calculations for the point estimate and 95% CI for risk vs. LET for 
males exposed at age 40 y. The top panel shows risks at an absorbed dose of 0.01 Gy, and the 
bottom panel shows risk at an absorbed dose of 0.1 Gy. The solid squares are the resulting “fold-
uncertainty” defined as the ratio of the 95% confidence level (CL) to the point estimate. At high 
LET, a five-fold uncertainty occurs at a low absorbed dose; at a higher absorbed dose and near 
the peak LET effectiveness, however, the uncertainties are reduced to about three-fold due to 
competing causes of death limiting the upper levels of risk from radiation. Figure 10 shows 
the REID dose response for iron ions (1000 MeV/u) and illustrates how curvature arises due 
to competing risks. 
 
NASA is considering various lunar and Mars missions as part of its exploration vision. 
An exploration concept is planned with missions to the Moon and Mars swingby and surface 
missions, respectively. Approximate characteristics of these missions used in our calculations are 
described in Table 4. Since the variation of GCR and SPE over the solar cycle would be difficult 
to use as a trade variable in long-term planning, we therefore discuss calculations at solar 
minimum and near solar maximum. We consider cancer risk calculations for Mars missions. For 
solar maximum calculations, we assume that the large SPE of August 1972 occurred during the 
interplanetary part of the mission, and use a solar modulation parameter (Badhwar et al., 1994a) 
of 1100 MV that is typical of about two years past solar maximum, when large SPEs often occur. 
SPE worst-case risks will be considered in Part II of this series of reports. Note that SPE 
exposures on the lunar surface are reduced by approximately one-half by the Moon itself, and on 
the Mars surface by more than one-half due to the planet and the Mars atmosphere. We use a 16 
g/cm2 vertical height for the Mars carbon dioxide atmosphere in our calculations. 
 
 
Table 4. Summary of mission parameters used for NASA exploration mission risk estimates 
Exploration 
mission 
Time period Total days Deep space 
days 
Lunar or Mars 
surface days 
LEO CEV test 2012–2015 6 6 (LEO) 0 
Lunar-short 2014–2020 14 6  8 
Lunar-long 2020–2030 90 6 84 
Mars swingby 2030–2040 600 600 0 
Mars surface 2030–2040 1000 400 600 
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Figure 8. Mass distributions in aluminum-equivalent depths: Left panel in Space Shuttle, ISS 
Service Module, and Skylab commander sleep compartment; and right panel for Apollo command 
module. 
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Figure 9. Calculations of REID vs. LET at doses of 0.01 or 0.1 Gy for 40-y males. 
Diamonds point estimates, bands 95% CI, and squares the fold uncertainties. 
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Figure 10. Dose response for point estimate and confidence levels for 
1-GeV/u iron ions showing curvature in the response at high risk levels 
due to competing risks. 
 
 
Table 5 shows fatal cancer risk projections at solar minimum for males and females of 
age 40 y at the time of the mission. Cancer morbidity risks are about 50% higher than mortality 
risks described here. Calculations are made for minimally shielded spacecraft of 5 g/cm2 alumi-
num and a heavily shielded spacecraft of 20 g/cm2. Similar calculations near solar maximum are 
shown in Table 6; an SPE fluence equivalent to the August 1972 SPE is assumed to have occur-
red. At solar minimum, it is seen that a four-fold addition of mass reduces the cancer risk by only 
about 15%. Results differ at solar maximum, where a four-fold increase in shielding mass leads to 
a more than two-fold reduction in cancer risk; solar protons are less penetrating than GCR and ef-
fectively mitigated by shielding. However, for heavy shielding (≥ 20 g/cm2), GCR dominates over 
SPEs and further addition of shielding provides marginal reductions. Each SPE is unique in that it 
has distinct fluence, energy spectra, and dose rates; therefore, the shielding thickness where GCR 
doses exceed SPE doses varies from event to event. 
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Table 5a. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are at solar minimum for a 5-g/cm2 aluminum 
shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
    Males (40 y) 
Lunar-long 0.03 0.084 0.34 [0.10, 1.2] 
Mars 
swingby 
0.37 1.03 4.0 [1.0, 10.5] 
Mars 
surface 
0.42 1.07 4.2  [1.3, 13.6] 
    Females (40 y) 
Lunar-long 0.03 0.084 0.41 [0.12, 1.5] 
Mars 
swingby 
0.37 1.03 4.9 [1.4, 16.2] 
Mars 
surface 
0.42 1.07 5.1  [1.6, 16.4] 
 
 
Table 5b. Calculations of effective doses, REID, and 95% CI for lunar 
or Mars missions. Calculations are at solar minimum for a 20-g/cm2 
aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
    Males (40 y) 
Lunar-long 0.03 0.071 0.28 [0.09, 0.95] 
Mars 
swingby 
0.36 0.87 3.2 [1.0, 10.4] 
Mars 
surface 
0.41 0.96 3.4  [1.1, 10.8] 
    Females (40 y) 
Lunar-long 0.03 0.071 0.34 [0.11, 1.2] 
Mars 
swingby 
0.36 0.87 3.9 [1.2, 12.7] 
Mars 
surface 
0.41 0.96 4.1  [1.3, 13.3] 
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Table 6a. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are near solar maximum assuming 1972 SPE 
in deep space segment of mission with a 5-g/cm2 aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
  Males (40 y) 
Lunar-long 0.45 0.69 2.7 [0.95, 7.6] 
Mars 
swingby 
0.62 1.21 4.4 [1.5, 13.1] 
Mars 
surface 
0.66 1.24 4.8 [1.6, 14.2] 
  Females (40 y) 
Lunar-long 0.45 0.69 3.3 [1.1, 9.3] 
Mars 
swingby 
0.62 1.21 5.7 [1.8, 17.1] 
Mars 
surface 
0.66 1.24 5.8 [2.0, 17.3 ] 
 
 
Table 6b. Calculations of effective doses, REID, and 95% CI for lunar or 
Mars missions. Calculations are near solar maximum assuming 1972 SPE 
in deep space segment of mission with a 20-g/cm2 aluminum shield 
Exploration 
mission 
D, Gy E, Sv REID(%) 95% CI 
  Males (40 y) 
Lunar-long 0.04 0.09 0.36 [0.12, 1.2] 
Mars 
swingby 
0.22 0.54 2.0 [0.60, 6.8] 
Mars 
surface 
0.25 0.60 2.4 [0.76, 7.8] 
  Females (40 y) 
Lunar-long 0.04 0.09 0.43 [0.13, 1.4] 
Mars 
swingby 
0.22 0.54 2.5 [0.76, 8.3] 
Mars 
surface 
0.25 0.60 2.9 [0.89, 9.5] 
 
 
An alternative to a shielding approach that adds mass is to optimize materials used in 
spacecraft structures or planetary habitats to reduce radiation risk. Figure 11 shows PDFs for the 
GCR as solar minimum for aluminum, polyethylene, and liquid hydrogen shielding with areal 
density of 20 g/cm2. Table 7 shows results for the χ2 statistic comparing polyethylene and hydro-
gen shielding effectiveness to aluminum. For calculations that ignore the low-LET risk coefficient 
uncertainties, near solar maximum with a large SPE, significant results (P<0.01) are found for 
liquid hydrogen and for the GCR at solar minimum (with P<0.15). We conclude that, because 
of the modest differences between polyethylene and aluminum as GCR absorbers and the large 
radiobiological uncertainties in cancer risk projection models, the benefits of polyethylene com-
pared to aluminum shielding for GCR cannot be proven at this time. A key factor in these results 
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is that, although aluminum is a greater producer of secondary radiation compared to polyethylene, 
tissue shielding “equalizes” many of these differences. 
 
The formalism can be applied to estimate the number of days a mission is ensured to be 
below an exposure limit at a given confidence level. Because we use the REID quantity and the 
newer Life-Span Study of the Atomic-Bomb Survivors, LSS Report 13 (Preston et al., 2003) 
values for ELR and EAR compared to NCRP Report 132 (NCRP, 2000) and consider limits for 
single missions rather than 10-year careers, we first calculated dose limits that result for the 
present model corresponding to 3% and 5% fatal cancer risk for missions of length <3 y. These 
are listed in Table 8, which also shows calculations of LLE from radiation-induced cancers. In an 
earlier report (Cucinotta, et al., 2000b), we estimated the maximum number of days in deep space 
that astronauts could spend with a 95% CL to remain below a 3% fatal cancer risk. Table 9 updates 
these calculations and compares them to the earlier report. These results show a significant in-
crease in the number of “safe” days, with 95% CL to remain below acceptable levels or risk that 
result from our improved methodology. However, the results still fall well short of those needed 
for a Mars mission. 
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Figure 11. PDFs for 40-y males on Mars swingby mission of 600 days 
for 20-g/cm2 shields of aluminum, polyethylene, or liquid hydrogen. Ef-
fective doses, point estimates, and 95% CI for REID are shown in box. 
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Table 7a. χ2 test at solar minimum for 20- g/cm2 shields for 40-y 
males on Mars swingby mission. P(n, χ2) is the probability materials 
cannot be determined to be significantly different (n=500). Values in 
bold for P(n, χ2)<0.2 indicate a significant improvement over 
aluminum 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All uncertainties 
Aluminum 0.87 3.2 [1.0, 10.5] – – 
Polyethylene 0.78 2.9 [0.94, 9.2] 0.05 >0.99 
Hydrogen 0.43 1.6 [0.52, 5.1] 0.63 >0.99 
 LET-dependent uncertainties 
Aluminum 0.87 3.2 [1.9, 8.7] – – 
Polyethylene 0.78 2.9 [1.8, 7.5] 0.08  >0.99 
Hydrogen 0.43 1.7 [1.0, 4.2] 1.10 <0.15 
 
 
Table 7b. Same as Table 7a near solar maximum for 5-g/cm2 shields 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All uncertainties 
Aluminum 1.21 4.4 [1.5, 13.1] – – 
Polyethylene 0.94 3.5 [1.2, 10.8] 0.14 >0.99 
Hydrogen 0.52 2.1 [0.60, 6.4] 0.81 >0.99 
 LET-dependent uncertainties 
Aluminum 1.21 4.4 [3.0. 11.0] – – 
Polyethylene 0.94 3.5 [2.3, 8.8] 0.32 >0.99 
Hydrogen 0.52 2.1 [1.2, 5.2] 1.38 <0.001 
 
 
Table 7c. Same as Table 7a near solar maximum for 20-g/cm2 shields 
Test Material E, Sv REID(%) 95% CL χ2/n P(n,χ2)   
 All uncertainties 
Aluminum 0.54 2.0 [0.60, 6.8] – – 
Polyethylene 0.45 1.7 [0.52, 5.6] 0.08 >0.99 
Hydrogen 0.24 0.9 [0.27, 2.9] 0.77 >0.99 
 LET-dependent uncertainties 
Aluminum 0.54 2.0 [1.2, 5.6] – – 
Polyethylene 0.45 1.7 [1.0, 4.6] 0.15 >0.99 
Hydrogen 0.24 0.9 [0.52, 2.4] 1.26 <0.005 
 
 
Table 8a. Example career effective dose limits in units of Sievert for one-year 
missions and corresponding average life-loss for an exposure-induced death 
 E, Sv for 3% REID (average life loss per death, y) 
Age, y Males Females 
25 0.5  (15.7) 0.4 (15.9) 
30 0.6  (15.4) 0.5 (15.7) 
35 0.7  (15.0)  0.55 (15.3) 
40 0.8  (14.2) 0.6 (14.7) 
45 0.95  (13.5)  0.75 (14.0) 
50 1.15  (12.5) 0.9 (13.2) 
55 1.5  (11.5) 1.1 (12.2) 
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Table 8b. Example career effective dose limits in units of Sievert for one-year 
missions and corresponding average life-loss for an exposure-induced death 
 E, Sv for 5% REID (average life loss per death, y) 
Age, y Males Females 
25 0.9  (15.7) 0.6 (15.9) 
30 1.0  (15.4) 0.8 (15.7) 
35 1.2  (15.0) 0.9 (15.3) 
40 1.3  (14.2) 1.0 (14.7) 
45 1.6  (13.5)  1.25 (14.0) 
50 1.9  (12.5) 1.5 (13.2) 
55   2.45 (11.5) 1.9 (12.2) 
 
 
Table 9a. Projections for males of age-dependent maximum days in deep space with 95% CL 
of remaining below a risk limit, RL(%). Calculations are for GCR at solar minimum with 10-g/cm2 
aluminum shielding comparing previous results (Cucinotta et al., 2001b) to present results 
Age, y Previous RL=3% Present RL= 3% Present RL= 5% 
30 91 142 236 
35 104 166 277 
40 122 186 310 
45 148 224 373 
50 191 273 455 
55 268 340 568 
 
 
Table 9b. Projections for females of age-dependent maximum days in deep space with 95% CL 
of remaining below a risk limit, RL(%). Calculations are for GCR at solar minimum with 10-g/cm2 
aluminum shielding comparing previous results (Cucinotta et al., 2001b) to present results 
Age, y Previous RL=3% Present RL= 3% Present RL= 5% 
30 54 112 187 
35 62 132 220 
40 73 150 250 
45 89 182 304 
50 115 224 374 
55 159 282 470 
 
 
6.  Discussion and Recommendations 
 
The building of PDFs that propagate errors from individual factors that contribute to 
uncertainties in projection models is a powerful tool for managing radiation risks, including eval-
uating benefits of research and mitigation approaches and implementing the radiation protection 
principle of as low as reasonable achievable (ALARA). The uncertainties estimated here are 
reduced compared to our previous estimates (Cucinotta et al., 2001b, 2002, 2004) for the 
following reasons: 
 
1. Use of the REID rather than radiation cancer rates (decreases upper uncertainty level 
because of role of competing risks). 
2. Use of trial Q(L) functions rather than uncorrelated uncertainties as a function of LET 
(overall decrease in uncertainties). 
3. Neglect of NCRP “unknown” uncertainties (decrease in uncertainties). 
4. Redefining LET spectra uncertainties (modest increase in uncertainties). 
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However, these estimates should be viewed as preliminary because of the need to assess 
additional uncertainties that have not been included in the analysis, including protraction effects, 
scaling of ERRs or EARs estimated from low-LET data to high LETs, and the potential impact of 
a healthy worker effect. These factors will need to be considered in future work. Research at the 
NSRL will have a major impact on reducing uncertainties by establishing a basic understanding 
for extrapolating experimental data to humans, and by providing important data for reducing the 
major uncertainties described above (i.e., dose-rate effects and quality factors). Low-LET epide-
miology data and physics models uncertainties have a smaller role in the present evaluation. As 
noted in our earlier report (Cucinotta et al., 2001b), other uncertainties exist in the representation 
of radiation shielding composition and predicting future solar cycle effects or the characteristics 
of SPEs; however, these are more practical in nature and will be considered elsewhere. 
 
The methodologies used for risk assessment ultimately play a large role in the esti-
mates of uncertainties and shielding effectiveness. The use of the linear-additivity model is a key 
assumption in the current methodology. This model has a strong theoretical basis and is 
consistent with mouse carcinogenesis studies with low-dose neutron irradiations (Storer and Fry, 
1995). For neutron exposures, a mixed low- and high-LET field is present due to the gamma-ray 
component produced by neutrons and this would not be representative of the spectral and temporal 
patterns of GCR. Possible deviations from the linear-additivity model for the GCR spectrum 
along with correlations in estimates of DDREF, protraction effects, and quality factors need to be 
considered in future work. Experiments that simulate the constant high-energy proton background 
and variable dose-rate SPEs with interspersed heavy nuclei irradiation such as iron would be a 
first step in testing these effects. The NCRP model (NCRP, 2000) applies a DDREF of only two 
for total doses less than 200 mGy or dose-rates less than 0.1 mGy/min. The former condition is 
not met for the Mars missions or for a large SPE, and should be investigated in future work. 
Further investigation of alternative methodologies that could possibly reduce uncertainty 
estimates should also be considered. The use of Bayesian statistics combined with track structure 
models to explore the replacement of Q(L) functions with Q functions dependent on charge and 
LET or kinetic energy, and the resulting effects on uncertainties will also be described in a future 
report. Alternative methodologies, including ones that study cancer incidence at specific tissue 
sites, should allow additional biological factors to enter risk models—perhaps lowering 
uncertainty estimates. However, the need for new biological data and understanding is the most 
important approach to reducing uncertainties. 
 
 For exploration missions outside LEO, higher risks from radiation may be unavoidable 
because of the longer durations where high GCR exposures will occur and the potential risks 
from SPEs. In this report we have discussed radiation limits using the alternative quantity REID 
instead of the ELR of fatal cancer used in the past. The REID is recommended because it is more 
directly comparable to other mission risks, especially when supplemented with information on the 
average life-loss per death, LLER. The LLER estimates provided in Table 8 are likely lower bounds 
because high-LET radiation effects are known to occur with reduced latency compared to gamma-
rays from which these estimates are based. Research to make accurate estimates of LLER values 
as a function of exposure and tumor type will be important for mission risk assessments. 
 
Career radiation limits and shielding requirements could also be impacted by new 
knowledge of fatal non-cancer risks from radiation exposure such as heart disease (Preston et 
al., 2003; Howe et al., 2004; Yang and Ainsworth, 1982) or damage to the CNS. Based on the 
Japanese survivor data (Preston et al., 2003), non-cancer risks are estimated to be small for the 
shorter lunar missions, but could lead to a significant risk for a Mars mission. The risk of heart 
disease for ions is largely unknown because only one report (considered a pilot study by its 
authors) has been made on the effects of HZE ions on heart disease (Yang and Ainsworth, 1982), 
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and human data for low-LET radiation at low dose-rates is inconclusive on the level of risk to be 
expected (Howe et al., 2004; Cardis et al., 1995). CNS risks have the potential to impact both 
short-term and career radiation limits and mitigation approaches (NRC, 1996), but it will be 
several years before radiobiological research will provide sufficient knowledge on CNS risks 
to be used operationally by NASA. 
 
 As new experimental data and models of cancer risks are obtained from the NSRL, we 
expect to see a significant reduction in estimates of uncertainties compared to the estimates cited 
in this report. There are, however, limitations on the extent of uncertainty reduction that can be 
achieved by using population-based estimates. In future, the need for performing individual-based 
risk assessment will grow if uncertainties less than about two-fold are to be achieved. A major con-
clusion of this report is that funding of ground-based space radiobiology research to reduce the 
uncertainties in risk projections remains the most cost-effective approach for achieving goals 
in radiation safety, including ensuring that risk mitigation approaches are validated. 
 
We have shown that, with regard to the GCR, the optimization of material selection 
and mass cannot be put on a sound scientific basis because the reductions estimated from point 
estimates alone are only on the order of 10–30% for most shielding materials, and, when com-
bined with uncertainties in projection models, non-significant results for risk reduction are found. 
It still may be reasonable to assume that risk is reduced when comparing hydrocarbon shields to 
aluminum or other metals, but application of ALARA is problematic since a cost-benefit analysis 
cannot be properly performed under these conditions. In contrast, for acute risks, which are large-
ly an absorbed dose and dose-rate effect, SPEs are the major concern and the role of minimizing 
mass requirements through hydrocarbon shielding materials is easier to prove. We therefore rec-
ommend the following approach for radiation shielding designs until uncertainties are reduced 
to a degree that significance testing of shielding effectiveness can be based on PDFs: 
 
1. Exploration vehicles should be designed to reduce acute radiation risks from SPEs 
to well below a 30-day limit of 0.25 Gy-Eq using a worst-case SPE environment that 
will be discussed in Part II of this report. 
2. Secondary to SPE shielding should be the optimization of GCR shielding. A 
reduction of the following three quantities by more than 25% compared to aluminum 
should be considered to demonstrate sufficient value in alternative shielding 
materials: 
a. Effective dose (organ averaged). 
b. HZE fluence, F(E) for ions with Z>10. 
c. F(L) for L>30 keV/µm. 
d. Neutron fluence, F(E) between 0.1 to 20 MeV. 
 
The requirements in (a) through (d) above are partially redundant but are needed to ensure that 
the radiation components with the highest biological uncertainties are significantly reduced when 
evaluating GCR shielding concepts. Reductions of less than 25% could be considered if the costs 
for their implementation are low. 
 
The ALARA principle is an important aspect of radiation safety. Our estimate of 95% 
CLs to stay below limits can be used as criteria for a minimal ALARA requirement for the design 
of lunar missions, including transfer vehicle or surface habitat designs. For example, about a four-
fold margin can be used for GCR exposures and about a 2.5-fold margin can be used for SPEs. 
Detailed cost-benefit analysis should be used for measures that would provide even lower risks. 
Future work should consider a worst-case SPE environment, including the possibility of multiple 
SPEs as a function of mission duration. Based on the results of Table 9 and the above margins, 
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we conclude that “blind selection” of astronauts for lunar missions can be made for missions with 
a duration of fewer than 180 days for male or female astronauts above the age of 35 y if sufficient 
protection against SPEs is provided. Because of the higher GCR risks for Mars exploration and 
the likely impacts of non-cancer risks, no conclusions on ALARA goals for these missions or the 
possibility of “blind selection” can be made at this time. The inherent uncertainties in population-
based risk models and the higher risks on long-duration missions point to the likelihood that 
individual-based risk assessments will be needed for Mars exploration missions. 
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